8.98

5.15% +0.44

After Hours: 8.97 -0.010 -0.11%

Solid Biosciences Inc (SLDB)

Overview News Price History Option Chain Why SLDB Down? Discussions Forecast Stock Split

Solid Biosciences Inc stock is currently priced at $8.98, with a 24-hour trading volume of 189.87K. It has seen a +5.15% increased in the last 24 hours and a -33.82% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $8.37 pivot point. If it approaches the $9.04 resistance level, significant changes may occur.

Previous Close:

$8.54

Open:

$8.52

24h Volume:

189.87K

Market Cap:

$339.06M

Revenue:

$14.79M

Net Income/Loss:

$-96.02M

P/E Ratio:

-1.4539

EPS:

-6.1766

Net Cash Flow:

$-95.70M

1W Performance:

+3.22%

1M Performance:

-33.82%

6M Performance:

+349.00%

1Y Performance:

+91.06%

1D Range:

$8.41

$9.08

52W Range:

$1.81

$15.05

Solid Biosciences Inc Stock (SLDB) Company Profile

Name

Solid Biosciences Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

617-337-4680

Address

141 Portland Street, Fifth Floor, Cambridge, MA

Employee

Twitter

@SolidBioDMD

Next Earnings Date

2024-05-09

Latest SEC Filings

SLDB's Discussions on Twitter

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-12-21	Initiated	Piper Sandler	Neutral
May-27-21	Initiated	Jefferies	Buy
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-09-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform
Aug-29-19	Downgrade	Citigroup	Neutral → Sell
Aug-19-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Aug-16-19	Upgrade	Chardan Capital Markets	Neutral → Buy
May-14-19	Downgrade	Credit Suisse	Neutral → Underperform
May-14-19	Downgrade	Goldman	Neutral → Sell
Feb-08-19	Upgrade	Citigroup	Sell → Neutral
Feb-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-18	Initiated	Citigroup	Sell
Sep-06-18	Initiated	Credit Suisse	Neutral

View All

Solid Biosciences Inc Stock (SLDB) Latest News

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug

Zacks Investment Research

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

GlobeNewswire Inc.

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday

Benzinga

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

GlobeNewswire Inc.

Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus

Zacks Investment Research

Solid Biosciences Inc Stock (SLDB) Financials Data

Solid Biosciences Inc (SLDB) Revenue 2024

SLDB reported a revenue (TTM) of $14.79 million for the quarter ending June 30, 2022.

Solid Biosciences Inc (SLDB) Net Income 2024

SLDB net income (TTM) was -$96.02 million for the quarter ending December 31, 2023, a -11.67% decrease year-over-year.

Solid Biosciences Inc (SLDB) Cash Flow 2024

SLDB recorded a free cash flow (TTM) of -$95.69 million for the quarter ending December 31, 2023, a +5.24% increase year-over-year.

Solid Biosciences Inc (SLDB) Earnings per Share 2024

SLDB earnings per share (TTM) was -$4.84 for the quarter ending December 31, 2023, a +52.03% growth year-over-year.

Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.